KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals Inc

KALV - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$1.44B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
KalVista Pharmaceuticals IncKalVista Pharmaceuticals Inc-8.4-4539%13.5-104.8
$21.88

Current Fair Value

19% downside

Overvalued by 19% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$1.44 Billion
Enterprise Value$1.49 Billion
Earnings per Share$-3.23
Beta-0.29
Outstanding Shares50,536,000

Return

Return on Equity4539.43%ROE
Return on Assets-36.69%
Return on Invested Capital-45.56%

Valuation & Multiples

P/E Ratio-8.36P/E Ratio
PEG9.32PEG
Price to Sales13.5Price to Sales
Price to Book Ratio-27.0Price to Book Ratio
Enterprise Value to Revenue12.31
Enterprise Value to EBIT-11.78
Enterprise Value to Net Income-13
Total Debt to Enterprise0.19
Debt to Equity-104.83Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
September 3, 2026
EPS Estimate
$-0.38
Consensus analyst estimate
Revenue Estimate
$39.14 M
Consensus analyst estimate

Next Earnings Call

Expected Date
December 3, 2026
EPS Estimate
$-0.29
Consensus analyst estimate
Revenue Estimate
$48.66 M
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.64, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.6415▲ 50.36%
Total Calls1,618,200▲ 1438.21%
Total Puts1,038,000▲ 7058.62%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %137.03%▲ 5.49%
Total Invested$1.39B▲ 28.90%
Investors Holding192▲ 27.00%

About KalVista Pharmaceuticals Inc

CEO: Thomas Crockett

KalVista Pharmaceuticals Insider Information FAQ

Stockcircle tracks 1 top investor with a current 13F position in KalVista Pharmaceuticals. Holdings come from the latest quarterly 13F filings filed with the SEC.

In the latest 13F quarter on Stockcircle, 3 top investors reduced or sold among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Stockcircle shows 13 open-market insider sales for KalVista Pharmaceuticals in the last six months from SEC Form 4 reports by executives, directors, and other insiders.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.